ÌÇÐÄvlog

Object moved to here.

Endovascular Thrombectomy as a Means to Improve Survival in Acute Ischemic Stroke: A Meta-analysis | Cerebrovascular Disease | JAMA Neurology | ÌÇÐÄvlog

ÌÇÐÄvlog

[Skip to Navigation]
Sign In
1.
Bracard ÌýS, Ducrocq ÌýX, Mas ÌýJL, Ìýet al; THRACE Investigators. ÌýMechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial.ÌýÌý³¢²¹²Ô³¦±ð³Ù Neurol. 2016;15(11):1138-1147. doi:
2.
Campbell ÌýBC, Mitchell ÌýPJ, Kleinig ÌýTJ, Ìýet al; EXTEND-IA Investigators. ÌýEndovascular therapy for ischemic stroke with perfusion-imaging selection.ÌýÌýN Engl J Med. 2015;372(11):1009-1018. doi:
3.
Saver ÌýJL, Goyal ÌýM, Bonafe ÌýA, Ìýet al; SWIFT PRIME Investigators. ÌýStent-retriever thrombectomy after intravenous t-PA vs t-PA alone in stroke.ÌýÌýN Engl J Med. 2015;372(24):2285-2295. doi:
4.
Jovin ÌýTG, Chamorro ÌýA, Cobo ÌýE, Ìýet al; REVASCAT Trial Investigators. ÌýThrombectomy within 8 hours after symptom onset in ischemic stroke.ÌýÌýN Engl J Med. 2015;372(24):2296-2306. doi:
5.
Mocco ÌýJ, Zaidat ÌýOO, von Kummer ÌýR, Ìýet al; THERAPY Trial Investigators. ÌýAspiration thrombectomy after intravenous alteplase versus intravenous alteplase alone.ÌýÌý³§³Ù°ù´Ç°ì±ð. 2016;47(9):2331-2338. doi:
6.
Berkhemer ÌýOA, Fransen ÌýPS, Beumer ÌýD, Ìýet al; MR CLEAN Investigators. ÌýA randomized trial of intraarterial treatment for acute ischemic stroke.ÌýÌýN Engl J Med. 2015;372(1):11-20. doi:
7.
Powers ÌýWJ, Rabinstein ÌýAA, Ackerson ÌýT, Ìýet al; American Heart Association Stroke Council. Ìý2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.ÌýÌý³§³Ù°ù´Ç°ì±ð. 2018;49(3):e46-e110. doi:
8.
Ibanez ÌýB, James ÌýS, Agewall ÌýS, Ìýet al; ESC Scientific Document Group. Ìý2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation of the European Society of Cardiology (ESC).ÌýÌýEur Heart J. 2018;39(2):119-177. doi:
9.
Nogueira ÌýRG, Jadhav ÌýAP, Haussen ÌýDC, Ìýet al; DAWN Trial Investigators. ÌýThrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct.ÌýÌýN Engl J Med. 2018;378(1):11-21. doi:
10.
Albers ÌýGW, Marks ÌýMP, Kemp ÌýS, Ìýet al; DEFUSE 3 Investigators. ÌýThrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging.ÌýÌýN Engl J Med. 2018;378(8):708-718. doi:
11.
Goyal ÌýM, Demchuk ÌýAM, Menon ÌýBK, Ìýet al; ESCAPE Trial Investigators. ÌýRandomized assessment of rapid endovascular treatment of ischemic stroke.ÌýÌýN Engl J Med. 2015;372(11):1019-1030. doi:
12.
Kidwell ÌýCS, Jahan ÌýR, Gornbein ÌýJ, Ìýet al; MR RESCUE Investigators. ÌýA trial of imaging selection and endovascular treatment for ischemic stroke.ÌýÌýN Engl J Med. 2013;368(10):914-923. doi:
13.
Goyal ÌýM, Menon ÌýBK, van Zwam ÌýWH, Ìýet al; HERMES Collaborators. ÌýEndovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials.ÌýÌý³¢²¹²Ô³¦±ð³Ù. 2016;387(10029):1723-1731. doi:
14.
Román ÌýLS, Menon ÌýBK, Blasco ÌýJ, Ìýet al; HERMES Collaborators. ÌýImaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data.ÌýÌý³¢²¹²Ô³¦±ð³Ù Neurol. 2018;17(10):895-904. doi:
15.
van den Berg ÌýLA, Dijkgraaf ÌýMG, Berkhemer ÌýOA, Ìýet al; MR CLEAN Investigators. ÌýTwo-year outcome after endovascular treatment for acute ischemic stroke.ÌýÌýN Engl J Med. 2017;376(14):1341-1349. doi:
Views 2,444
Brief Report
April 8, 2019

Endovascular Thrombectomy as a Means to Improve Survival in Acute Ischemic Stroke: A Meta-analysis

Author Affiliations
  • 1Division of Cardiology, Pulmonology and Vascular Medicine, Department of Internal Medicine, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
  • 2Department of Neurology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
  • 3Department of Diagnostic and Interventional Radiology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany
  • 4Cardiovascular Research Institute Düsseldorf, Düsseldorf, Germany
JAMA Neurol. 2019;76(7):850-854. doi:10.1001/jamaneurol.2019.0525
Key Points

QuestionÌý Is there a benefit for short-term survival with endovascular thrombectomy vs medical therapy in acute ischemic stroke?

FindingsÌý In this meta-analysis of all randomized clinical trials of endovascular thrombectomy vs medical therapy cited in the 2018 American Stroke Association/American Heart Association guidelines for acute ischemic stroke, endovascular thrombectomy significantly reduced the risk for 90-day mortality compared with medical therapy, without a difference in risk of intracranial hemorrhage.

MeaningÌý There is considerable evidence of the benefits of endovascular thrombectomy for survival during the first 90 days after acute ischemic stroke.

Abstract

ImportanceÌý Although endovascular thrombectomy (EVT) in acute ischemic stroke is recommended by guidelines to improve functional recovery, thus far there are insufficient data on its association with mortality.

ObjectiveÌý To identify guideline-relevant trials of EVT vs medical therapy reporting 90-day mortality and perform a meta-analysis.

Data SourcesÌý All randomized clinical trials cited for recommendations on EVT vs medical therapy in the latest 2018 American Stroke Association/American Heart Association guidelines.

Study SelectionÌý Ten American Stroke Association/American Heart Association guideline–relevant randomized clinical trials of EVT vs medical therapy were selected for inclusion. Two EVT trials were excluded owing to infrequent use of EVT.

Data Extraction and SynthesisÌý Data were abstracted by 2 independent investigators and double-checked by 4 others. Singular study data were integrated using the Cochran-Mantel-Haenszel method and a random-effects model to compute summary statistics of risk ratios (RR) with 95% CIs.

Main Outcomes and MeasuresÌý Risk of 90-day mortality and 90-day intracranial hemorrhage was analyzed; sensitivity analyses were performed in early-window EVT trials (which included patients from the onset of symptoms onward) vs late-window EVT trials (which included patients from 6 hours after onset of symptoms onward).

ResultsÌý In 10 trials with 2313 patients, EVT significantly reduced the risk for 90-day mortality by 3.7% compared with medical therapy (15.0% vs 18.7%; RR, 0.81; 95% CI, 0.68-0.98; P = .03). Trends were similar in early-window (RR, 0.83; 95% CI, 0.67-1.01; P = .06) and late-window trials only (RR, 0.76; 95% CI, 0.41-1.40; P = .38). There was no difference in the risk for intracranial hemorrhage in EVT vs medical therapy (4.2% vs 4.0%; RR, 1.11; 95% CI, 0.71-1.72; P = .65). Limitations of the studies include trial protocol heterogeneity and bias originating from prematurely terminated trials.

Conclusions and RelevanceÌý This meta-analysis of all evidence on EVT cited in the 2018 American Stroke Association/American Heart Association guidelines shows significant benefits for survival during the first 90 days after acute ischemic stroke compared with medical therapy alone.

×